Previous Article | Next Article 
Journal of Virology, February 1999, p. 1617-1623, Vol. 73, No. 2
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Identification of Directly Infected Cells in the
Bone Marrow of Neonatal Moloney Murine Leukemia Virus-Infected Mice by
Use of a Moloney Murine Leukemia Virus-Based Vector
Michael A.
Okimoto and
Hung
Fan*
Department of Molecular Biology and
Biochemistry and Cancer Research Institute, University of
California, Irvine, California 92697-3900
Received 14 May 1998/Accepted 17 October 1998
 |
ABSTRACT |
Early bone marrow infection of Moloney murine leukemia virus
(M-MuLV)-infected mice was studied. Previous experiments indicated that
early bone marrow infection is essential for the efficient development
of T lymphoma. In order to identify the cellular pathway of infection
in the bone marrow, infection of mice with a helper-free replication-defective M-MuLV-based retroviral vector was carried out.
Such a vector will undergo only one round of infection, without spreading to other cells; thus, cells infected by the initially injected virus (directly infected cells) can be identified. For these
experiments, the BAG vector that expresses bacterial
-galactosidase was employed. Neonatal NIH/Swiss mice were inoculated intraperitoneally with ca. 106 infectious units of a BAG vector pseudotyped
with M-MuLV proteins, and bone marrow cells were recovered 2 to 12 days
postinfection. Single-cell suspensions were tested for infection by
staining with X-Gal
(5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside) or by immunofluorescence with an anti-
-galactosidase antibody. Two
sizes of infected cells were evident: large multinucleated cells and
small nondescript (presumptively hematopoietic) cells. Secondary stains
for lineage-specific markers indicated that the large cells were
osteoclasts. Some of the small cells expressed nonspecific esterase,
which placed them in the myeloid lineage, but they lacked markers for
hematopoietic progenitors (mac-1, gr-1, sca-1, and CD34). These results
provide evidence for primary M-MuLV infection of osteoclasts or
osteoclast progenitors in the bone marrow, and they suggest that known
hematopoietic progenitors are not primary targets for infection.
However, the subsequent spread of infection to hematopoietic
progenitors was indicated, since bone marrow from mice infected in
parallel with replication-competent wild-type M-MuLV showed detectable
infection in small cells positive for mac-1 or CD34, as well as in osteoclasts.
 |
INTRODUCTION |
Moloney murine leukemia virus
(M-MuLV) is a simple retrovirus that induces T lymphoma in susceptible
mice. Leukemogenesis by M-MuLV has been studied extensively (reviewed
in reference 6). It has become clear that it is a
multistep process, with several well-defined events taking place in an
orderly fashion. Two well-recognized events include the insertional
activation of proto-oncogenes and the generation of polytropic envelope
recombinants (MCF recombinants [7]) in the infected animal.
We have employed an enhancer variant of M-MuLV, Mo+PyF101 M-MuLV,
to study M-MuLV leukemogenesis in mice. This virus contains enhancer
sequences from the F101 strain of murine polyoma virus inserted into
the M-MuLV long terminal repeat downstream of the M-MuLV enhancers
(11). Mo+PyF101 M-MuLV shows substantially attenuated
leukemogenicity when inoculated subcutaneously (s.c.) into newborn mice
(3, 5). Comparative studies with Mo+PyF101 and wild-type
M-MuLV have identified a series of preleukemic events induced by wild-type M-MuLV, notably hematopoietic hyperplasia in
the spleen. The splenic hyperplasia appears to result secondarily from
stromal defects in the bone marrow (10). The leukemogenic defect of Mo+PyF101 M-MuLV is also dependent on the route of
inoculation. When Mo+PyF101 M-MuLV is inoculated s.c. it shows
attenuation; when inoculated intraperitoneally (i.p.) it shows
leukemogenicity equivalent to that of wild-type M-MuLV (1).
Comparative studies of mice inoculated s.c. and i.p. with Mo+PyF101
M-MuLV provided further insight (1). The rate of infection
for Mo+PyF101 M-MuLV in the thymus (the ultimate target organ for
M-MuLV leukemogenesis) did not differ between s.c. and i.p.
inoculation. On the other hand, early infection (1 to 2 weeks) in the
bone marrow was substantially reduced in mice infected s.c. with
Mo+PyF101 M-MuLV compared to those infected by the i.p. route. This
indicated that early bone marrow infection is essential for efficient
leukemogenesis by M-MuLV. One possibility is that the bone marrow might
seed infection to lymphoid precursors that subsequently migrate to the thymus.
In light of the identification of the bone marrow as a critical target
for M-MuLV infection, we were interested in a more detailed
characterization of early bone marrow infection. In particular, we were
interested in identifying the cell types that become infected and the
order in which this occurs. To identify the first cells infected, we
employed a replication-defective M-MuLV-based retroviral vector
(BAG) that expresses a readily detectable reporter gene, the gene that
encodes bacterial
-galactosidase. In vivo infection with this vector
allows the identification of cells that are directly infected by the
injected virus, since the vector cannot spread to other cells.
Infection of the bone marrow after i.p. inoculation with an
M-MuLV-based retroviral vector is characterized in this report.
 |
MATERIALS AND METHODS |
Viruses and inoculation of mice.
Psi-2 cells (12)
were transfected by a plasmid containing the BAG vector (kindly
provided by Constance Cepko [15]) and were selected
for the presence of the vector by growth in a medium containing G418.
G418-resistant cells were grown in Dulbecco modified Eagle's medium
(DMEM) supplemented with 10% calf serum as described previously
(15). The cell culture supernatant was harvested and
concentrated 10- to 20-fold by ultrafiltration with an Amicon Centriprep 50 (Amicon Inc., Beverly, Mass.). To titrate viral supernatants, serial dilutions were used to infect NIH/3T3 cells that
had been pretreated for 1 h with 20 µg of Polybrene per ml. Cells were allowed to grow until confluence and were stained for
-galactosidase activity as described below, and the number of blue
colonies was counted. Viral vector titers of 2 × 106
to 6 × 106 infectious units/ml were routinely obtained.
These viral supernatants were used to inoculate neonatal NIH/Swiss mice
i.p. (200 µl per animal). Mice were sacrificed at various days
postinoculation, and bone marrow was flushed from both femurs of each
mouse with phosphate-buffered saline (PBS) in a 23-gauge needle. Bone
marrow cells were washed three times with DMEM-10% calf serum and
were then deposited onto glass slides for cell staining by
cytocentrifugation. Between 2 × 105 and 5 × 105 bone marrow cells was deposited on each slide, and the
entire slide was scanned in a light or fluorescence microscope.
Cell staining and immunofluorescence.
-Galactosidase
activity in cells was detected by staining with X-Gal
(5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside) as described by Price et al. (15). Briefly, after
cytocentrifugation onto slides, cells were fixed with 0.5%
paraformaldehyde in PBS and then stained with an X-Gal reaction mixture
containing 1 mg of X-Gal (Gibco) per ml, 15 mM potassium ferrocyanide,
15 nM potassium ferricyanide, and 1 mM MgCl2. Staining was
performed at 37°C for 6 to 8 h.
Staining of cell preparations for nonspecific esterase (NSE) and
tartrate-resistant acid phosphatase (TRAPase) staining were
carried out
with commercial assay kits (a naphthol AS-D chloroacetate
esterase kit
and an

-naphthyl acetate esterase and acid phosphatase,
leukocyte
kit, respectively) according to the manufacturer's instructions
(Sigma
Diagnostics, St. Louis, Mo.). Acetylcholinesterase (AChE)
staining was
performed as described previously (
4). Briefly,
10 mg of
acetylthiocholine iodide (Calbiochem, La Jolla, Calif.)
was dissolved
in 15 ml of 100 mM sodium phosphate buffer (pH 6.0),
1 ml of 100 mM
sodium citrate, 2 ml of 30 mM copper sulfate, and
2 ml of 5 mM
potassium ferricyanide. Slides were incubated in
this solution for
3 h at room temperature in the
dark.
For immunofluorescence staining, cells were fixed with 50%
methanol-50% acetone after cytocentrifugation. After extensive
washing
with PBS, cells were blocked with 3% normal goat serum
(NGS) in PBS
for 2 to 3 h. Primary antibodies in 3% NGS were then
added and
allowed to incubate overnight at 4°C. After the overnight
incubation,
cells were washed with PBS-1% NGS and then incubated
with fluorescein
isothiocyanate (FITC)- or Texas red-conjugated
secondary antibodies in
3% NGS for 1 to 2 h. After incubation
with the secondary
antibodies, the cells were washed as before
and visualized by
fluorescence microscopy with the appropriate
filters. In all
experiments, cell preparations from uninfected
mice were stained in
parallel as negative controls. For some antibodies
there was little
staining of uninfected cells, while for others
(e.g.,

-galactosidase) low-level binding to uninfected cells
was observed.
The following antibodies were used: rat monoclonal
antibodies to mac-1
(Boehringer Mannheim), CD34, gr-1, or sca-1
(Pharmingen, La Jolla,
Calif.), a rabbit polyclonal antibody to

-galactosidase (5'3',
Boulder, Colo.), and a rabbit polyclonal
antibody to M-MuLV capsid
antigen (CA) (
13).
Osteoclast cultures.
To promote osteoclast outgrowth, cells
flushed from mouse femurs were grown on glass coverslips in 24-well
plates for 7 to 10 days at 37°C in DMEM containing 10% fetal bovine
serum and 10 nM 1
,25-dihydroxycholicalciferol as described by Hata
et al. (8).
 |
RESULTS |
To identify the first cells infected by M-MuLV in the bone marrow
of neonatal mice, a replication-defective M-MuLV-based retroviral vector was used. The BAG vector developed by Price et al.
(15) expresses bacterial
-galactosidase as a fusion with
the M-MuLV Gag protein (Fig. 1). When the
BAG vector plasmid is transfected into Psi-2 packaging cells
(15), the resulting virus particles consist of M-MuLV
proteins with BAG vector RNA. The BAG vector produced by these cells
would infect the same cells that wild-type M-MuLV does, but it would
not spread past the initially infected cells, since the vector does not
encode all of the M-MuLV proteins necessary for productive infection.

View larger version (6K):
[in this window]
[in a new window]
|
FIG. 1.
BAG vector. The organization of the BAG vector
(15) in its proviral form is shown. The vector contains the
bacterial -galactosidase gene (lac z) and a selectable
marker (the bacterial neomycin phosphotransferase gene
[neor] under the control of the simian virus
40 [SV40] promoter). For these experiments, the plasmid DNA
containing the BAG vector sequences was transfected into Psi-2
packaging cells. LTR, long terminal repeat; pBR ori, origin of
replication.
|
|
BAG vector was prepared by harvesting the supernatant from stably
transfected Psi-2/BAG cells, followed by the clarification and
concentration procedures described in Materials and Methods. Infectious
agent titers of 2 × 106 to 6 × 106/ml were obtained. The BAG vector stocks were free of
replication-competent M-MuLV, as measured by XC syncytial plaque assays.
Neonatal NIH/Swiss mice were inoculated i.p. with BAG vector (ca.
106 infectious units/animal). This route of infection is a
standard way of inducing leukemia by M-MuLV and one that leads to early high-level bone marrow infection in M-MuLV-infected mice. At various times postinfection (2 to 12 days), the animals were sacrificed and
bone marrow flushes from their femurs were harvested. Single-cell suspensions (2 × 105 cells) were deposited onto
microscope slides by cytocentrifugation and then stained with X-Gal to
detect infected cells (which were stained blue and were visible under
light microscopy). Within 2 days postinfection, blue cells that were
either large or small could be detected (Fig.
2A and B). The small BAG-infected cells were morphologically indistinct and resembled the majority of cells in
the bone marrow. The large BAG-infected cells were irregular in shape
after cytocentrifugation and were either mono- or multinucleate. Based
on their size, the large cells could be either large tissue macrophages, megakaryocytes, or osteoclasts. When bone marrow from age-matched uninfected mice was analyzed in parallel, no blue cells were evident after X-Gal staining.

View larger version (157K):
[in this window]
[in a new window]
|
FIG. 2.
X-Gal staining of BAG-infected bone marrow cells.
Neonatal mice were infected i.p. with 5 × 105
infectious units of BAG vector. Six days postinfection, the animals
were sacrificed and single-cell suspensions from the bone marrow were
deposited on microscope slides by cytocentrifugation. The slides were
then stained with X-Gal with or without secondary histochemical stains.
(A and B) X-Gal staining alone, showing large and small BAG-infected
cells (the blue stain is indicated by arrows). (C) Staining of a slide
for both -galactosidase and NSE (reddish stain). The arrow indicates
a cell that is simultaneously stained positive for -galactosidase
and NSE. (D) Staining of a slide for both -galactosidase and AChE.
In this slide, a hematoxylin-eosin counterstain was used to visualize
all cells (purple color). The open arrow shows an AChE-positive
megakaryocyte (reddish stain); in the same field, a large
X-Gal-stained cell (the blue stain is indicated by the solid arrow) is
also seen. None of the X-Gal-stained cells were also positive for AChE.
Bar, 10 µm.
|
|
The total number of BAG-infected cells in the bone marrow of animals
after i.p. inoculation is shown in Fig.
3. Although there was variation between
different infected animals, there appeared to be a general increase in
infected cells between 2 and 8 days postinfection, with typical maximal
numbers ranging from 102 to 103 infected cells
per animal. The increase might have reflected the influx into the bone
marrow of BAG-infected cells or alternatively the division of infected
cells already in the bone marrow. Likewise, a potential decrease in
infected cells between 8 and 12 days postinfection could have reflected
the turnover of BAG-infected cells or their emigration from the bone
marrow.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 3.
Numbers of BAG-infected cells per animal. The total
number of BAG-infected cells in each animal's marrow were calculated
as the number of X-Gal-stained cells in 2 × 105 cells
(the total number of bone marrow cells recovered). Results for
individual animals are plotted as a function of the number of days
postinfection.
|
|
To further characterize the BAG-infected bone marrow cells, secondary
histochemical stains were performed. NSE is a histochemical stain used
to identify cells of the myeloid lineage (4). Myeloid cells
that would stain positive for NSE include monocytes, macrophages, and
immature osteoclasts (preosteoclasts). Mature osteoclasts (from adult
mice) have not been reported to stain positive for NSE. Bone marrow
cells from BAG-infected mice were stained first with X-Gal and then for
NSE and were screened for the presence of cells that stained positive
for both (double positive). As shown in Fig. 2C, doubly stained cells
could be detected. Quantification of the doubly stained cells is shown
in Table 1; a percentage of both large
and small BAG-infected cells stained positive for NSE, indicating that
they were in the myeloid lineage. A total of 17% of the small
BAG-infected cells were double positive, and 8% of the large
BAG-infected cells were double positive.
Since the large BAG-infected cells were potentially
megakaryocytes, double staining with AChE, a marker for
megakaryocytes, was carried out. When bone marrow cells from
BAG-infected mice were stained with X-Gal and for AChE, no doubly
infected cells were found (Fig. 2D). In addition, the morphology of the
AChE-positive cells was different from that of the BAG-infected cells.
The AChE-positive cells were regular and even after cytocentrifugation,
compared to the irregular appearance of the BAG-infected cells. Thus,
it appeared that the large BAG-infected cells were not megakaryocytes.
It was also interesting to examine BAG-infected bone marrow by staining
for TRAPase. TRAPase is a marker for osteoclasts (20), cells
in the bone responsible for bone resorption and derived from cells of
the myeloid lineage (16). Indeed, peripheral monocytes or
macrophages can be induced to differentiate into osteoclasts when
cocultured with bone marrow stromal cell lines (19).
Unfortunately, the conditions for X-Gal staining and TRAPase staining
were incompatible, so double histochemical staining could not be
performed. However, when TRAPase staining by itself was carried out,
large irregular multinucleated cells, as well as small cells, stained
positive (Fig. 4). The morphology of the
large TRAPase-positive cells resembled that of the large BAG-positive
cells. This supported the possibility that the large BAG-positive cells
were osteoclasts. Another phenotypic marker that has been described on
osteoclast precursors is the CD34 antigen. As shown below, a
substantial fraction of the large BAG-positive cells were also CD34
positive.

View larger version (104K):
[in this window]
[in a new window]
|
FIG. 4.
TRAPase staining of infected bone marrow. A
cytocentrifuge preparation of bone marrow from a BAG-infected mouse was
stained for TRAPase. The figure shows two darkly stained osteoclasts
(one large and one small). Note that the large osteoclast is
multinucleate and irregular in shape. Bar, 10 µm.
|
|
To further characterize the BAG-infected cells, double
immunofluorescent staining with an antibody to
-galactosidase, in combination with monoclonal antibodies specific for lineage-specific cell surface markers, was carried out. As shown in Fig.
5, the anti-
-galactosidase antibody
detected BAG-infected cells in the bone marrow preparations. Both large
and small BAG-infected cells were detected by immunofluorescent
staining (Fig. 5C and E), and the numbers of infected cells were
equivalent to those detected by X-Gal staining.

View larger version (87K):
[in this window]
[in a new window]
|
FIG. 5.
Immunofluorescent staining of infected bone marrow.
Cytocentrifuge preparations were made from BAG-infected mouse bone
marrow. Two-color immunofluorescence microscopy was carried out with a
rabbit polyclonal antibody for -galactosidase (with an
FITC-conjugated secondary antibody), along with lineage-specific
monoclonal rat antibodies (with a Texas red-conjugated secondary
antibody). (A) Staining with FITC-conjugated secondary antibody alone.
(B) Staining with the anti- -galactosidase antibody of bone marrow
from an uninfected mouse. In some other slides, this antibody produced
nonspecific staining at the periphery of all cells; specific staining
was evident as homogeneous cytoplasmic staining (see other panels). (C
and D) Simultaneous staining of the same field for -galactosidase,
photographed through a green filter (C), and for mac-1 antigen,
photographed through a red filter (D). Note the large cell that is
stained positive for -galactosidase but not mac-1. (E and F)
Simultaneous staining of the same field for -galactosidase (E) and
mac-1 (F). A small -galactosidase-positive cell did not stain
positive for mac-1 (arrows). Other mac-1-positive cells are evident in
panels D and F. Insets in panels E and F show a higher magnification of
the region around the arrows. (G and H) Simultaneous staining of the
same field for -galactosidase (G) and CD34 antigen (H). Note the
large -galactosidase-positive cell that stained positive for CD34.
Bar, 10 µm.
|
|
Double immunofluorescent staining of BAG-infected bone marrow with an
anti-
-galactosidase antibody and a monoclonal antibody for mac-1
antigen was carried out. mac-1 is expressed on cells of the myeloid
lineage, including myeloid progenitors and terminally differentiated
macrophages. The large BAG-infected cells in the bone marrow did not
stain positive for mac-1 (Fig. 5D), although numerous mac-1-positive
cells were detected (Fig. 5D and F). This further supported the
conclusion that the large BAG-infected cells in the bone marrow were
not macrophages. Although osteoclast progenitors belong to the myeloid
lineage, mature osteoclasts do not express mac-1 (14).
Therefore, the results of the mac-1 staining supported the conclusion
that the large BAG-infected cells might be osteoclasts.
Somewhat surprisingly, the small BAG-infected bone marrow cells also
did not stain positive for mac-1 (only 1 of 31 examined; see below).
Given the fact that some of the small BAG-infected cells were NSE
positive (assigning them to the myeloid lineage), it had seemed likely
that they would be mac-1 positive as well. One possible explanation is
that some of the small infected cells were preosteoclasts that had
down-regulated the expression of mac-1 but had not yet lost NSE activity.
Given the indications that the large BAG-infected bone marrow cells
were osteoclasts, staining for CD34 and mac-2 antigens was of interest.
Previous reports indicated that osteoclasts from freshly isolated bone
marrow of adult mice express mac-2 (14). However, when bone
marrow cells from uninfected or BAG-infected neonatal mice were tested,
no mac-2-positive cells were detected. Thus, neonatal mouse osteoclasts
are apparently mac-2 negative. However, when bone marrow from
BAG-infected mice was cultured in vitro in a medium containing
1
,25-dihydroxycholicalciferol, a vitamin D analog that promotes the
outgrowth and differentiation of osteoclasts (19), large
BAG-positive cells that also contained mac-2 could be detected readily
(Fig. 6C and D). Approximately 70% of
the BAG-positive cells in the osteoclast cultures were mac-2 positive.
A high percentage of the cells in these in vitro cultures (ca. 50%)
also stained positive for TRAPase (Fig. 6G), confirming the outgrowth
of osteoclasts. These results indicate that neonatal osteoclasts can be
induced to express mac-2, and they further supported the identification
of the large BAG-infected cells as osteoclasts.

View larger version (72K):
[in this window]
[in a new window]
|
FIG. 6.
Staining of in vitro-differentiated osteoclasts from
BAG-infected mice. Bone marrow cells from BAG-infected mice were
cultured in vitro on glass slides with 1 ,25-dihydroxycholicalciferol
to induce osteoclast differentiation. Two-color immunofluorescent
staining is shown. (A) Staining of the culture with secondary
FITC-conjugated antibody alone. (B) Staining of a culture from an
uninoculated animal for -galactosidase. (C and D) Two-color
staining of the same field for -galactosidase (C) and
mac-2 antigen (D). A large double-positive cell is evident. (E
and F) Two-color staining of the same field for -galactosidase
(E) and CD34 antigen (F). Two double-positive cells are evident. (G)
Staining of a slide from the same in vitro culture for TRAPase. Bar, 10 µm.
|
|
CD34 has been reported to be present in osteoclast precursors
(17). A significant fraction of the large BAG-infected cells were CD34 positive (Fig. 5G and H), further supporting the
identification of the large BAG-infected cells as osteoclasts. As
expected, a high percentage of the in vitro-differentiated osteoclasts
from BAG-infected neonatal mice were CD34 positive (Fig. 6E and F).
Double immunofluorescent staining was used to investigate further the
nature of the small BAG-infected cells. Given their size and location
in the bone marrow, it seemed likely that they might be hematopoietic
precursors. To test for multipotential hematopoietic precursors,
staining for sca-1 and CD34 was carried out. sca-1 is expressed on the
earliest (self-renewing) hematopoietic precursors (18),
while CD34 is expressed on more committed multipotential progenitors as
well as stromal cells in the bone marrow (17). As shown in
Table 2, no small BAG-infected cells
expressed either sca-1 or CD34, indicating that early hematopoietic
progenitors were not infected.
Staining with an additional hematopoietic lineage-specific monoclonal
antibody was also carried out (Table 2). gr-1 antigen is a marker for
committed granulocytic precursors; this was of interest in light
of the NSE-positive small BAG-infected cells (presumptively myeloid). However, no BAG-infected cells showed staining
for this marker, although other noninfected gr-1-positive cells in the
bone were readily detected. Therefore, these experiments did not
provide any evidence for the BAG infection of myeloid or multipotential
hematopoietic progenitors. In limited preliminary experiments, none of
the small BAG-infected bone marrow cells expressed the lymphoid markers
Thy-1 and B220, either.
Since all of the experiments described above involved the helper-free
BAG vector, it was important to test if bone marrow from mice infected
with wild-type M-MuLV showed evidence of infection of the same cell
types. Therefore, neonatal mice were infected i.p. with wild-type
M-MuLV (1.0 × 106 PFU/animal, as measured by XC
assay), and 2 to 14 days postinfection, bone marrow cells were examined
by immunofluorescent staining with an antibody specific for M-MuLV CA
protein. As with the BAG-infected animals, both large and small
M-MuLV-infected cells were detected (Fig. 7C and
E). Some of the large M-MuLV-infected
cells also stained positive for CD34 (Fig. 7D and Table 2), although
the percentage of CD34-positive osteoclasts was lower for
M-MuLV-infected animals than for BAG-infected animals. These results
support the conclusion that osteoclasts are primary targets of
infection by M-MuLV in the bone marrow after i.p. infection of neonatal
mice. It was also interesting that in the M-MuLV-infected mice,
significant numbers of small infected cells showed staining for the
other hematopoietic markers (Fig. 7F and Table 2). This was
particularly notable for mac-1, where approximately 24% (5 of 21) of
the small M-MuLV-infected bone marrow cells stained positive for mac-1
versus approximately 3% (1 of 31) of the BAG-infected bone marrow
cells. In addition, while 0 of 33 small BAG-infected cells stained
positive for either gr-1 or CD34, 4 of 55 (7%) small M-MuLV-infected
cells stained positive for these markers. These results might reflect the secondary infection of hematopoietic progenitors from initially infected cells.

View larger version (107K):
[in this window]
[in a new window]
|
FIG. 7.
Immunofluorescent staining of bone marrow from
M-MuLV-infected mice. Cytocentrifuge preparations were made from
M-MuLV-infected mice 8 days postinfection. (A) Staining with secondary
FITC-conjugated antibody alone. (B) Staining with -galactosidase
antibody and FITC-conjugated secondary antibody of cells from
uninfected mice. (C and D) Simultaneous staining of the same field for
CA (C) and CD34 antigen (D). Note the large double-positive cell. Some
nonspecific binding of CA antibody to the periphery of cells is evident
at this photographic exposure (see also panel E). (E and F)
Simultaneous staining of the same field for CA (E) and mac-1 (F). Note
the small mac-1-infected cell (arrows). Insets in panels E and F show a
higher magnification of the region around the arrows. Bar, 10 µm.
|
|
 |
DISCUSSION |
In these experiments, the first cells infected in the bone marrow
of neonatal mice inoculated i.p. with M-MuLV were characterized. The
use of a replication-defective M-MuLV-based vector allowed the
identification of direct targets of infection
i.e., cells directly
infected by the injected virus
since infection could not spread beyond
those cells. One cell type in the bone marrow was identified as a
direct target of infection: the large infected cells were osteoclasts,
cells involved in bone resorption. BAG infection of osteoclasts was
deduced from a combination of criteria: (i) the size and morphology of
the large BAG-infected cells was consistent with those of
TRAPase-positive osteoclasts in primary bone marrow; (ii) the large
BAG-infected cells were positive for CD34, which is present on
osteoclasts and osteoclast precursors; (iii) in vitro differentiation
of infected bone marrow by 1
,25-dihydroxycholicalciferol yielded
BAG-infected cells that stained positive for CD34 as well as mac-2,
antigens characteristic of osteoclasts; and (iv) the large BAG-infected
cells lacked markers specific for other large bone marrow cells (AChE
and mac-1).
Small directly infected cells in the bone marrow were also detected,
but the identities of the small BAG-infected cells were less clear. It
is likely that some of them were osteoclast precursors, which would be
consistent with the staining of a fraction of them with NSE. However,
it was interesting that no evidence for primary infection of known
hematopoietic progenitors was obtained. The small BAG-infected cells
were negative for markers on multipotential progenitors (sca-1 and
CD34) and on committed ones (mac-1 and gr-1). On the other hand, in
adult mice infected neonatally with wild-type M-MuLV, there is
ample evidence for the infection of hematopoietic progenitors
(2). This suggests that the infection of hematopoietic
progenitors in the bone marrow may result from secondary spread from
osteoclasts or other directly infected cells. Indeed, the data in Fig.
7 and Table 2 demonstrating the presence of hematopoietic markers on
significant numbers of small M-MuLV-infected bone marrow cells support
this notion. Detailed time course experiments comparing the pattern of
infection by BAG and wild-type M-MuLV are in progress. An alternate
explanation is that hematopoietic progenitors lacking the markers
tested here were the initial targets of M-MuLV infection. It will
be interesting to culture BAG-infected bone marrow in vitro under
conditions that allow the growth of hematopoietic progenitor colonies
and to test if any of these colonies originated from BAG-infected cells.
What is the mechanism by which i.p. inoculation with the BAG vector led
to osteoclast infection? One possible explanation is that the
inoculated virions entered the circulation from the peritoneum and
traveled to the bone marrow, where they infected osteoclasts or
osteoclast progenitors. This seems rather unlikely, given the
relatively modest input titers of BAG vector and the likelihood that
many tissues could adsorb virus from the circulation. A more attractive
explanation is that the BAG vector infected an osteoclast progenitor in
the peritoneum and this infected progenitor subsequently migrated to
the bone marrow. One candidate for such a cell would be a peritoneal
macrophage or monocyte. It has been shown that peripheral macrophages
and monocytes can differentiate into osteoclasts in vitro when cultured
on bone marrow stromal lines (19).
It is unlikely that terminally differentiated osteoclasts are the
primary target for BAG and M-MuLV infection. Simple retroviruses such as M-MuLV require the passage of the infected cell through mitosis
to allow the breakdown of the nuclear envelope and the entry of the
preintegration complex into the nucleus (9). Thus, precursors to osteoclasts that are still cycling are the most likely targets.
These experiments also have implications for gene therapy involving
retroviral vectors. It has been previously demonstrated that
retroviral vectors can infect early hematopoietic progenitors in vitro
and that these vector-infected progenitors can drive hematopoiesis when
injected back into animals (21). Thus, it is plausible that
the direct injection of retroviral vectors into animals could also
efficiently target early hematopoietic progenitors. However the results
presented here indicate that the predominant bone marrow cells that are
directly infected after i.p. injection are osteoclasts. Moreover, small
vector-infected bone marrow cells lack the markers characteristic of
early hematopoietic progenitors (sca-1 and CD34).
While the experiments reported here identified osteoclasts as at least
one cell type initially infected by M-MuLV in the bone marrow after
i.p. inoculation, there were limitations to the conclusions. First, we
did not test whether the infected osteoclasts or osteoclast progenitors were productively infected. It was not possible to address
this question with the BAG vector, but it will be important to test if
osteoclasts or their progenitors infected by wild-type M-MuLV produce
infectious virus. Second, the initial motivation for these experiments
was to identify infected cells in the bone marrow that are important
for leukemogenesis by M-MuLV. The experiments reported here do not
address that issue directly, although they do provide the starting
point. Future experiments with modified vectors and viruses may provide
insight into this question.
 |
ACKNOWLEDGMENTS |
This work was supported by grant CA32455 from the National
Cancer Institute. M.A.O. was supported by NIH training grant 5 T32 AI07319. The support of the UCI Cancer Research Institute and
the Chao Family Comprehensive Cancer Center is gratefully acknowledged.
We thank Barbara Belli for advice and suggestions.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Biology and Biochemistry, Cancer Research Institute,
University of California, Irvine, CA 92697-3900. Phone: (949) 824-5554. Fax: (949) 824-4023. E-mail: hyfan{at}uci.edu.
 |
REFERENCES |
| 1.
|
Belli, B., and H. Fan.
1994.
The leukemogenic potential of an enhancer variant of Moloney murine leukemia virus varies with the route of inoculation.
J. Virol.
68:6883-6889[Abstract/Free Full Text].
|
| 2.
|
Brightman, B. K.,
B. R. Davis, and H. Fan.
1990.
Preleukemic hematopoietic hyperplasia induced by Moloney murine leukemia virus is an indirect consequence of viral infection.
J. Virol.
64:4582-4584[Abstract/Free Full Text].
|
| 3.
|
Brightman, B. K.,
A. Rein,
D. J. Trepp, and H. Fan.
1991.
An enhancer variant of Moloney murine leukemia virus defective in leukemogenesis does not generate detectable mink cell focus-inducing virus in vivo.
Proc. Natl. Acad. Sci. USA
88:2264-2268[Abstract/Free Full Text]. (Erratum, 88:5066.)
|
| 4.
|
Brown, B.
1984.
Hematology: principles and procedures.
Lea and Febiger, Philadelphia, Pa.
|
| 5.
|
Davis, B.,
E. Linney, and H. Fan.
1985.
Suppression of leukaemia virus pathogenicity by polyoma virus enhancers.
Nature
314:550-553[Medline].
|
| 6.
|
Fan, H.
1997.
Leukemogenesis by Moloney murine leukemia virus: a multistep process.
Trends Microbiol.
5:74-82[Medline].
|
| 7.
|
Hartley, J. W.,
N. K. Wolford,
L. J. Old, and W. P. Rowe.
1977.
A new class of murine leukemia virus associated with development of spontaneous lymphomas.
Proc. Natl. Acad. Sci. USA
74:789-792[Abstract/Free Full Text].
|
| 8.
|
Hata, K.,
T. Kukita,
A. Akamine,
A. Kukita, and K. Kurisu.
1992.
Trypsinized osteoclast-like multinucleated cells formed in rat bone marrow cultures efficiently form resorption lacunae on dentine.
Bone
13:139-146[Medline].
|
| 9.
|
Lewis, P. F., and M. Emerman.
1994.
Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus.
J. Virol.
68:510-516[Abstract/Free Full Text].
|
| 10.
|
Li, Q., and H. Fan.
1990.
Combined infection by Moloney murine leukemia virus and a mink cell focus-forming virus recombinant induces cytopathic effects in fibroblasts or in long-term bone marrow cultures from preleukemic mice.
J. Virol.
64:3701-3711[Abstract/Free Full Text].
|
| 11.
|
Linney, E.,
B. Davis,
J. Overhauser,
E. Chao, and H. Fan.
1984.
Non-function of a Moloney murine leukaemia virus regulatory sequence in F9 embryonal carcinoma cells.
Nature
308:470-472[Medline].
|
| 12.
|
Mann, R.,
R. C. Mulligan, and D. Baltimore.
1983.
Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.
Cell
33:153-159[Medline].
|
| 13.
|
Mueller-Lantzsch, N., and H. Fan.
1976.
Monospecific immunoprecipitation of murine leukemia virus polyribosomes: identification of p30 protein-specific messenger RNA.
Cell
9:579-588[Medline].
|
| 14.
|
Niida, S.,
N. Amizuka,
F. Hara,
H. Ozawa, and H. Kodama.
1994.
Expression of Mac-2 antigen in the preosteoclast and osteoclast identified in the op/op mouse injected with macrophage colony-stimulating factor.
J. Bone Miner. Res.
9:873-881[Medline].
|
| 15.
|
Price, J.,
D. Turner, and C. Cepko.
1987.
Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer.
Proc. Natl. Acad. Sci. USA
84:156-160[Abstract/Free Full Text].
|
| 16.
|
Shih, C., and G. W. Bernard.
1996.
Peripheral blood mononuclear cells develop into multinucleated osteoclasts in tissue culture.
Ant. Rec.
245:41-45.
|
| 17.
|
Silvestri, F.,
S. Banavali,
M. Baccarani, and H. D. Preisler.
1992.
The CD34 hemopoietic progenitor cell associated antigen: biology and clinical applications.
Haematologica
77:265-273[Medline].
|
| 18.
|
Spangrude, G. J.,
J. Klein,
S. Heimfeld,
Y. Aihara, and I. L. Weissman.
1989.
Two monoclonal antibodies identify thymic-repopulating cells in mouse bone marrow.
J. Immunol.
142:425-430[Abstract].
|
| 19.
|
Udagawa, N.,
N. Takahashi,
T. Akatsu,
H. Tanaka,
T. Sasaki,
T. Nishihara,
T. Koga,
T. J. Martin, and T. Suda.
1990.
Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells.
Proc. Natl. Acad. Sci. USA
87:7260-7264[Abstract/Free Full Text].
|
| 20.
|
Webber, D.,
I. P. Braidman,
W. R. Robertson, and D. C. Anderson.
1989.
The effect of tartrate on bone cell acid phosphatase activity: a quantitative cytochemical study.
J. Bone Miner. Res.
4:809-815[Medline].
|
| 21.
|
Williams, D. A.,
I. R. Lemischka,
D. G. Nathan, and R. C. Mulligan.
1984.
Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse.
Nature
310:476-480[Medline].
|
Journal of Virology, February 1999, p. 1617-1623, Vol. 73, No. 2
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ethelberg, S., Tzschaschel, B. D., Luz, A., Diaz-Cano, S. J., Pedersen, F. S., Schmidt, J.
(1999). Increased Induction of Osteopetrosis, but Unaltered Lymphomagenicity, by Murine Leukemia Virus SL3-3 after Mutation of a Nuclear Factor 1 Site in the Enhancer. J. Virol.
73: 10406-10415
[Abstract]
[Full Text]
-
Schmidt, J., Lumniczky, K., Tzschaschel, B. D., Guenther, H. L., Luz, A., Riemann, S., Gimbel, W., Erfle, V., Erben, R. G.
(1999). Onset and Dynamics of Osteosclerosis in Mice Induced by Reilly-Finkel-Biskis (RFB) Murine Leukemia Virus : Increase in Bone Mass Precedes Lymphomagenesis. Am. J. Pathol.
155: 557-570
[Abstract]
[Full Text]
-
Okimoto, M. A., Fan, H.
(1999). Moloney Murine Leukemia Virus Infects Cells of the Developing Hair Follicle after Neonatal Subcutaneous Inoculation in Mice. J. Virol.
73: 2509-2516
[Abstract]
[Full Text]